Keay Nakae
Stock Analyst at Chardan Capital
(3.37)
# 936
Out of 4,760 analysts
200
Total ratings
28.93%
Success rate
8.29%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Buy | $50 | $12.03 | +315.63% | 9 | Feb 28, 2025 | |
| RNA Avidity Biosciences | Maintains: Buy | $65 | $29.58 | +119.74% | 13 | Feb 28, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $300 | $238.74 | +25.66% | 11 | Feb 26, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 | $15.06 | +298.41% | 18 | Feb 11, 2025 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $6.70 | +108.96% | 15 | Feb 6, 2025 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $25 | $1.52 | +1,544.74% | 13 | Jan 29, 2025 | |
| SONN Sonnet BioTherapeutics Holdings | Maintains: Buy | $30 → $20 | $1.39 | +1,338.85% | 12 | Dec 20, 2024 | |
| PRQR ProQR Therapeutics | Maintains: Buy | $4 | $1.85 | +116.22% | 13 | Dec 12, 2024 | |
| SLN Silence Therapeutics | Maintains: Buy | $55 | $4.22 | +1,203.32% | 10 | Dec 10, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $4.5 → $5 | $3.06 | +63.40% | 11 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.35 | - | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1.25 | $0.72 | +74.00% | 8 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $1.46 | +447.95% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $4.00 | +400.00% | 7 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $1.95 | +207.69% | 6 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $5.72 | -12.59% | 2 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.23 | - | 5 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $13.28 | -54.82% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $20 | $0.59 | +3,289.83% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $5.53 | +894.58% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $10.65 | -6.10% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $5.71 | +1,432.40% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $0.55 | +2,278.34% | 3 | Feb 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $155 → $40 | $4.09 | +878.00% | 2 | Jun 30, 2020 |
Dyne Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $50
Current: $12.03
Upside: +315.63%
Avidity Biosciences
Feb 28, 2025
Maintains: Buy
Price Target: $65
Current: $29.58
Upside: +119.74%
Alnylam Pharmaceuticals
Feb 26, 2025
Maintains: Buy
Price Target: $300
Current: $238.74
Upside: +25.66%
Arrowhead Pharmaceuticals
Feb 11, 2025
Maintains: Buy
Price Target: $60
Current: $15.06
Upside: +298.41%
Coya Therapeutics
Feb 6, 2025
Maintains: Buy
Price Target: $14
Current: $6.70
Upside: +108.96%
SAB Biotherapeutics
Jan 29, 2025
Maintains: Buy
Price Target: $25
Current: $1.52
Upside: +1,544.74%
Sonnet BioTherapeutics Holdings
Dec 20, 2024
Maintains: Buy
Price Target: $30 → $20
Current: $1.39
Upside: +1,338.85%
ProQR Therapeutics
Dec 12, 2024
Maintains: Buy
Price Target: $4
Current: $1.85
Upside: +116.22%
Silence Therapeutics
Dec 10, 2024
Maintains: Buy
Price Target: $55
Current: $4.22
Upside: +1,203.32%
Arbutus Biopharma
Nov 20, 2024
Maintains: Buy
Price Target: $4.5 → $5
Current: $3.06
Upside: +63.40%
Nov 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.35
Upside: -
Nov 13, 2024
Maintains: Buy
Price Target: $1.25
Current: $0.72
Upside: +74.00%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $1.46
Upside: +447.95%
Nov 13, 2024
Maintains: Buy
Price Target: $20
Current: $4.00
Upside: +400.00%
Aug 9, 2024
Maintains: Buy
Price Target: $6
Current: $1.95
Upside: +207.69%
Jun 3, 2024
Maintains: Buy
Price Target: $5
Current: $5.72
Upside: -12.59%
Feb 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.23
Upside: -
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $13.28
Upside: -54.82%
Nov 10, 2022
Maintains: Buy
Price Target: $60 → $20
Current: $0.59
Upside: +3,289.83%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $5.53
Upside: +894.58%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $10.65
Upside: -6.10%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $5.71
Upside: +1,432.40%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $0.55
Upside: +2,278.34%
Jun 30, 2020
Downgrades: Neutral
Price Target: $155 → $40
Current: $4.09
Upside: +878.00%